Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated erectile dysfunction
(ED) drug branded “Mango,” is excited to announce its new
partnership with the Greater NY Chamber of Commerce (“GNYCC”) to
bring its flagship product, Mango, to New York as part of a major
nationwide push to drive accelerating sales growth and new avenues
of marketing for its core product portfolio.
New York consistently features in the top five
U.S. states for most erectile dysfunction medication sales.
Mangoceuticals is targeting accelerating nationwide sales and seeks
to enter the NY marketplace to augment the splash it is seeing in
its new Make America Hard Again campaign.
“This is an exciting time for Mangoceuticals as
we partner with one of the largest Chambers of Commerce in the U.S.
to drive sales growth and brand awareness and pursue new channels
of market penetration in one of the biggest regional markets in the
country,” commented Jacob Cohen, CEO and Co-Founder of
Mangoceuticals. “We have already established a strong presence in
NY on a brand basis, so it’s only fitting that our flagship Men’s
‘erectile function’ medication, Mango, will be our first core
product to benefit from a huge direct sales push in this pivotal
market.”
The Greater New York Chamber of Commerce
represents 30,000 business and civic leaders, each of whom will
receive complimentary access to Mango as the GNYCC launches their
new Men’s Health & Wellness committee. The GNYCC’s members and
partners are comprised of entrepreneurs, small, medium size, major
and international corporations, public officials, local, city,
state and federal agencies, foreign dignitaries, and
consulates.
In 2022, North America dominated the global
erectile dysfunction drugs market with the highest revenue share of
51.7% and the U.S. sexual wellness market size was valued at USD
11.0 billion in 2022 and is expected to grow at a compound annual
growth rate (CAGR) of 7.91% from 2023 to 2030, according to recent
analysis from Grand View Research.
“The Greater New York Chamber is proud to have
MangoRx come to New York and be an elite member as they seek to
help so many Americans across the Country with both erectile
function and the many health & wellness products they intend to
release,” commented Mark Jaffe, the President and CEO of the
Greater New York Chamber. “The NY launch of their flagship
medication to all of our members is just the tip of the iceberg for
MangoRx and the GNYCC.”
Management notes that MangoRx continues to
broaden and deepen its marketing and sales footprint, with its
latest partnership with GNYCC as one of many key steps to drive its
nascent nationwide push. This follows recent steps including its
appointment of the award winning Lucky Break PR firm, its
sponsorship relationships with leading social media and podcast
brands focused on the men’s demographic, such as Barstool Sports,
Only Stans, Pillow Talk and No Jumper, as well as the nationwide
launch of its “Make America Hard Again”
(www.MakeAmericaHardAgain.com) campaign. These steps pave the way
for the Company’s upcoming launch of its new sildenafil-based Mango
ED product, which contains the active ingredient found in Viagra™,
along with many other new and disruptive products now in the
pipeline.
About the Greater New York Chamber of
Commerce
The Greater New York Chamber of Commerce
represents 30,000 business and civic leaders comprising of
entrepreneurs, small, medium size, major and international
corporations, public officials, local, city, state and federal
agencies, foreign dignitaries, and consulates. It provides
in-person and online weekly networking receptions, breakfasts,
luncheons, seminars, and business expos.
The mission of the Chamber is to improve the
business climate and quality of life in the New York Metropolitan
Area for businesses, workers, residents, and visitors. It provides
valuable services to individuals, start-ups, entrepreneurs, small
businesses, and civic leaders who represent the backbone of the
Greater New York business community.
The Greater New York Chamber of Commerce is an
approved New York State Not for Profit entity. It operates under
Rule 501 C 6, as an exempt organization under the U.S. Internal
Revenue Code. It also maintains a charitable fund to help assist
local chambers, trade organizations and civic groups under IRS Rule
501 C 3 and a political action committee.
For more information, please visit
http://www.ny-chamber.com.
About Mango
Created using a special formulation featuring
the same active ingredient as in Cialis™ (Tadalafil), each part of
the Mango formulation plays a critical role in helping men achieve
optimum performance. We believe the key to our success lies in our
unique blend of ingredients, which are used in U.S. Food and Drug
Administration (“FDA”) approved drugs. Mango contains a combination
of Tadalafil, Oxytocin, and L-Arginine that have been traditionally
used to treat sexual dysfunction.
Mango is a prescription medication that must be
approved by a physician. After an individual has completed an
online tele-health visit, our network of medical providers will
review and approve a prescription if medically appropriate. Mango
is a rapidly dissolved tablet (RDT) that is absorbed orally. For
best results, we advise taking Mango at least 15 minutes before
engaging in sexual activity. Tadalafil, one of the main ingredients
in Mango, typically has effects that last up to 36 hours.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on
developing, marketing, and selling a variety of men's health and
wellness products and services via a secure telemedicine platform.
To date, the Company has identified men's wellness telemedicine
services and products as a growing sector and especially related to
the area of erectile dysfunction (ED). The Company has developed a
new brand of ED product under the brand name "Mango" (think: "Man,
Go!").
For more information, please visit www.MangoRx.com.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen, has majority voting control over the Company; risks related
to the significant number of shares in the public float, our share
volume, the effect of sales of a significant number of shares in
the marketplace, and the fact that the majority of our shareholders
paid less for their shares than the public offering price of our
common stock in our recent initial public offering; the fact that
we have a significant number of outstanding warrants to purchase
shares of common stock at $1.00 per share, the resale of which
underlying shares have been registered under the Securities Act of
1933, as amended; our ability to build and maintain our brand;
cybersecurity, information systems and fraud risks and problems
with our websites; changes in, and our compliance with, rules and
regulations affecting our operations, sales, marketing and/or our
products; shipping, production or manufacturing delays; regulations
we are required to comply with in connection with our operations,
manufacturing, labeling and shipping; our dependency on
third-parties to prescribe and compound our ED product; our ability
to establish or maintain relations and/or relationships with
third-parties; potential safety risks associated with our Mango ED
product, including the use of ingredients, combination of such
ingredients and the dosages thereof; the effects of high inflation,
increasing interest rates and economic downturns, including
potential recessions, as well as macroeconomic, geopolitical,
health and industry trends, pandemics, acts of war (including the
ongoing Ukraine/Russian conflict) and other large-scale crises; our
ability to protect intellectual property rights; our ability to
attract and retain key personnel to manage our business
effectively; our ability to maintain the listing of our common
stock on the Nasdaq Capital Market; overhang which may reduce the
value of our common stock; volatility in the trading price of our
common stock; and general consumer sentiment and economic
conditions that may affect levels of discretionary customer
purchases of the Company's products, including potential recessions
and global economic slowdowns. Although we believe that our plans,
intentions and expectations reflected in or suggested by the
forward-looking statements we make in this release are reasonable,
we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties.
More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended March 31, 2023. These
filings are available at www.sec.gov and at our website at
https://investors.mangorx.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social
media: https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficialOr just click here
to see why Orange is the new Blue:
https://www.mangorx.com
FOR PUBLIC RELATIONS Lucky Break Public
Relations Sahra Simpson Sahra@luckybreakpr.com (323) 602-0091 ext.
704
FOR INVESTOR RELATIONS Mangoceuticals Investor
Relations Email: investors@mangorx.com
MEDIA CONTACT PHOENIX MGMT Marketing &
Consulting info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Mangoceuticals (NASDAQ:MGRX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024